Neurogene Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Neurogene Inc. (NGNE) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $104.13 million as of 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Notes › Investments › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2017-08-08
- 2017-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $104.13M.
- 2017-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $100.67M.
- 2016-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $70.76M.
- 2016-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $59.71M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One as first filed |
|---|---|---|
| 2017-06-30 | $104.13M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $100.67M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $70.76M 10-Q · filed 2017-08-08 | |
| 2016-09-30 | $59.71M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $44.09M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $33.02M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $34.96M 10-K · filed 2017-03-09 | |
| 2015-09-30 | $8.04M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $14.11M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $20.14M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $24.19M 10-K · filed 2016-03-14 | $24.19M 10-K · filed 2015-03-16 |
| 2013-12-31 | $2.82M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |